Given the low incidence of DKA in cardiovascular outcome trials and in hospitalized patients with DM-2 [16], coupled with the abundance of pertinent, recently published studies and existing uncertainties surrounding the administration of SGLT-2 inhibitors during acute illness, this systematic review seeks to furnish evidence on the utilization of SGLT-2i in patients experiencing acute illness, with a particular focus on SARS-CoV-2 infection. The gene discussed is SLC5A2; the disease is myotonic dystrophy type 2.